Phaseline

Companies › Shanghai UniXell Biotechnology

Shanghai UniXell Biotechnology: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 1; Neurology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
UX-DA001
Human midbrain dopaminergic progenitor cells that differentiate into mature dopaminergic n
–Phase 1Parkinson Disease, IdiopathicDec 2027
UX-GIP001
Allogeneic human GABAergic interneuron precursor cells
–Phase 1EpilepsyJul 2029
UX-DA003
Human allogeneic iPSC-derived midbrain dopaminergic progenitor cells
–Phase 1Parkinson's DiseaseAug 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06778265UX-DA001Phase 1Parkinson Disease, IdiopathicNeurologyDec 2027
NCT07572812UX-GIP001Phase 1EpilepsyNeurologyJul 2029
NCT07733349UX-DA003Phase 1Parkinson's DiseaseNeurologyAug 2029

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.